W warfarin war-far-in (Apo-Warfarin , Coumadin, Jantoven, Novo-Warfarin ) BLACK BOX ALERT May cause major or fatal bleeding. Risk factors include history of GI bleeding, hypertension, cerebrovascular disease, heart disease, malignancy, trauma, anemia, renal insufficiency, age 65 yrs and older, high anticoagulation factor (INR greater than 4). Consider cardiac/hepatic function, age, nutritional status, concurrent medications, risk of bleeding when dosing warfarin. Genetic variations have been identified as factors associated with dosage and bleeding risk. Genotyping tests are available. Do not confuse Coumadin with Kemadrin, or Jantoven with Janumet or Januvia. classification PHARMACOTHERAPEUTIC: Coumarin derivative. CLINICAL: Anticoagulant (see p. 33C). Action Interferes with hepatic synthesis of vitamin K–dependent clotting factors, resulting in depletion of coagulation factors II, VII, IX, X. Therapeutic Effect: Prevents further extension of formed existing clot; prevents new clot formation, secondary thromboembolic complications. Pharmacokinetics Route Onset Peak Duration PO 1.5–3 days 5–7 days 2–5 days Well absorbed from GI tract. Protein binding: 99%. Metabolized in liver. Primarily excreted in urine. Not removed by hemodialysis. Half-life: 20–60 hrs. Uses Prophylaxis, treatment of venous thrombosis, pulmonary embolism, and thromboembolic disorders. Prophylaxis, treatment of thromboembolic complications associated with cardiac valve replacement or atrial fibrillation. Reduces risk of death, recurrent MI, stroke, embolization after MI. OFF-LABEL: Treatment adjunct in transient ischemic attacks. Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window) Related Related posts: D U P I Stay updated, free articles. Join our Telegram channel Join Tags: Saunders Nursing Drug Handbook 2015 Mar 8, 2017 | Posted by admin in NURSING | Comments Off on W Full access? Get Clinical Tree
W warfarin war-far-in (Apo-Warfarin , Coumadin, Jantoven, Novo-Warfarin ) BLACK BOX ALERT May cause major or fatal bleeding. Risk factors include history of GI bleeding, hypertension, cerebrovascular disease, heart disease, malignancy, trauma, anemia, renal insufficiency, age 65 yrs and older, high anticoagulation factor (INR greater than 4). Consider cardiac/hepatic function, age, nutritional status, concurrent medications, risk of bleeding when dosing warfarin. Genetic variations have been identified as factors associated with dosage and bleeding risk. Genotyping tests are available. Do not confuse Coumadin with Kemadrin, or Jantoven with Janumet or Januvia. classification PHARMACOTHERAPEUTIC: Coumarin derivative. CLINICAL: Anticoagulant (see p. 33C). Action Interferes with hepatic synthesis of vitamin K–dependent clotting factors, resulting in depletion of coagulation factors II, VII, IX, X. Therapeutic Effect: Prevents further extension of formed existing clot; prevents new clot formation, secondary thromboembolic complications. Pharmacokinetics Route Onset Peak Duration PO 1.5–3 days 5–7 days 2–5 days Well absorbed from GI tract. Protein binding: 99%. Metabolized in liver. Primarily excreted in urine. Not removed by hemodialysis. Half-life: 20–60 hrs. Uses Prophylaxis, treatment of venous thrombosis, pulmonary embolism, and thromboembolic disorders. Prophylaxis, treatment of thromboembolic complications associated with cardiac valve replacement or atrial fibrillation. Reduces risk of death, recurrent MI, stroke, embolization after MI. OFF-LABEL: Treatment adjunct in transient ischemic attacks. Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window) Related Related posts: D U P I Stay updated, free articles. Join our Telegram channel Join Tags: Saunders Nursing Drug Handbook 2015 Mar 8, 2017 | Posted by admin in NURSING | Comments Off on W Full access? Get Clinical Tree
classification
